Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AER001 + AER002
- Development stage
- Discontinued
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AER001 + AER002 is an investigational combination of two long-acting, fully human IgG1 monoclonal antibodies, AER001 (also known as P5C3) and AER002 (also known as P2G3), originally discovered by Lausanne University Hospital (CHUV) and Ecole Polytechnique Fédérale de Lausanne (EPFL) and developed by Aerium Therapeutics. Both antibodies target non-overlapping epitopes on the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein, competing with angiotensin-converting enzyme 2 (ACE2) to block viral attachment and entry into host cells. The antibodies are engineered with the LS modification (Met428Leu/Asn434Ser) to extend their in vivo half-life. The combination was evaluated in a Phase 1 trial for the pre-exposure prophylaxis and treatment of COVID-19, particularly in immunocompromised individuals. However, development was discontinued after Aerium Therapeutics ceased operations in July 2024 due to the loss of neutralization activity against emerging Omicron subvariants.
- Other names
- AER001 and AER002AER-001 and AER002AER 001 and AER002P5C3 + P2G3P5C3 and P2G3P-5C3 and P2G3P 5C3 and P2G3
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on AER001 + AER002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AER001 + AER002.